Booke mark this website!
home my account view cart otc Welcome! - Login Register
Toll Free Tel: 1-877-270-3784
Toll Free Fax: 1-877-777-9144 . 1-877-703-3005
Drug Search
McAfee Secure sites help keep you safe from identity theft, credit card fraud, spyware, spam, viruses and online scams Privacy Policy by TRUSTe

Click to Call

Download
Order Forms

Get Adobe Acrobat


Buy Abilify Buy Advair
Buy Cialis Buy Flovent
Buy Geodon Buy Januvia
Buy Levaquin Buy Lipitor
Buy Lovenox Buy Nasonex
Buy Nexium Buy Plavix
Buy Singulair Buy Seroquel
Buy Viagra Buy Vytorin
Buy Zetia 

4 Tips to Keep Your Heart Healthy

How to Minimize Risk of Heart Disease

Healthy Winter Diet for Strong Immune System

Does Caffeine Benefit or Worsen Depression?

Choosing an Online Canadian Pharmacy

Canadian Online Pharmacies

How To Find A Canadian Internet Pharmacy

Cheap Canadian Drugs

Top 10 Most Popular
Over the Counter meds


Canada drugs



Share/Bookmark

Are Drug Companies Charging Too Much?



In recent days, much has been made of the case concerning 26 year-old Lucas Maciesza, the young man suffering from a rare and fatal blood disorder who is unable to obtain the Canadian drug Soliris, because being able to afford the drug is beyond him and his family’s reach. While the hospital has since stepped in to pay for at least his first few months of the Canada drug, the government has been pilloried for dragging its feet for so long on the issue. But should the pharmaceutical company making the Canadian drug be the one under fire for the prohibitive amount it is charging for its life saving product?

“If I was in government and has absolute control, I would tell the drug companies that they had to show me the figures to justify the cost,” notes York University professor of health policy, Joel Lexchin. “They’re entitled to a reasonable return, but I certainly wouldn’t start paying that kind of money without seeing some reason why it’s so expensive.”

The “kind of money” Lexchin is referring to is an extraordinary cost of half a million dollars annually to keep just one patient on the Canada drug. John Haslam, the general manager of Alexiom Pharma Canada, the company that produces Soliris, predictably believes the costs are justified. “Because of the large costs and extensive risks of developing drugs for patients with ultra rare disease, reimbursement levels need to be commensurately higher,” he says. He’s not the only who thinks so, though, with Barry Katsof, a patient who will need the drug every year for the rest of his life, very much in agreement with him. “The drug company has done their job,” he comments. “Now it’s up to the government to step up to the plate to do their job.”
Canada Drug Center | How To Order | Customer Care | About Pharmacy | Contact Pharmacy
Policies | Sitemap | Over The Counter Meds | Blog

CanadaDrugCenter Pharmacy Accreditation


Copyright © 2007-2017 by CanadaDrugCenter.com - All rights reserved.